Takeda Pharmaceutical Company Limited (TAKEDA) income statement
JPX · Healthcare · Drug Manufacturers - Specialty & Generic · 47,029 employees · CEO Julie So-Young Kim
- Price
- ¥6,651.00 +2.78%
- Market cap
- ¥10.6T
- Enterprise value
- ¥14.8T
- Last report
- Q2 '26 filed 2026-09-30
- Next report
- 2027-01-28 EPS est. ¥88.42
Takeda Pharmaceutical Company Limited (TAKEDA) reported revenue of ¥1.19T for Q2 '26 (+6.7% year on year), operating income of ¥205B (17.3% of revenue) and net income of ¥192B. Over the last four quarters revenue was ¥4.69T.
Income statement
| Income statement | Trend | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | Q2 '26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | ¥1.11T | ¥1.05T | ¥1.21T | ¥1.18T | ¥1.14T | ¥1.05T | ¥1.11T | ¥1.11T | ¥1.19T | ¥1.09T | ¥1.22T | ¥1.19T | |
| Cost of revenue | ¥513B | ¥516B | ¥550B | ¥537B | ¥552B | ¥511B | ¥516B | ¥380B | ¥401B | ¥561B | ¥407B | ¥392B | |
| Gross profit | ¥598B | ¥535B | ¥658B | ¥639B | ¥592B | ¥542B | ¥590B | ¥733B | ¥791B | ¥534B | ¥813B | ¥795B | |
| Research & development | ¥187B | ¥196B | ¥168B | ¥176B | ¥170B | ¥216B | ¥144B | ¥161B | ¥175B | ¥195B | ¥167B | ¥171B | |
| Other operating expenses | ¥1.21B | ¥0 | ¥0 | ¥0 | ¥0 | ¥0 | ¥0 | ¥249B | ¥164B | ¥0 | ¥158B | ¥147B | |
| Operating expenses | ¥456B | ¥481B | ¥438B | ¥444B | ¥441B | ¥512B | ¥400B | ¥664B | ¥622B | ¥487B | ¥612B | ¥590B | |
| Operating income | ¥142B | ¥53.4B | ¥220B | ¥195B | ¥152B | ¥30.5B | ¥191B | ¥69B | ¥169B | ¥46.7B | ¥201B | ¥205B | |
| Interest income | ¥22.6B | ¥5.99B | ¥30.7B | ¥4.12B | ¥0 | ¥18.7B | ¥73.8B | ¥44.4B | ¥87.9B | ¥5.15B | ¥24.6B | ¥14.6B | |
| Interest expense | ¥67.3B | ¥47.2B | ¥59.7B | ¥68.5B | ¥31.6B | ¥50.3B | ¥107B | ¥83.1B | ¥124B | ¥43.6B | ¥63.8B | ¥63.4B | |
| Other non-operating income (gains on investments, FX ...) | ¥14.3B | ¥57.5B | ¥22.7B | ¥7.1B | ¥91.6B | ¥86.7B | -¥67.7B | -¥42.3B | -¥88.7B | ¥55.5B | -¥25.1B | -¥14B | |
| Total non-operating income | -¥80.6B | -¥101B | -¥83.1B | -¥76.1B | -¥125B | -¥138B | -¥40B | -¥40.8B | -¥35B | -¥99.2B | -¥38.7B | -¥49.4B | |
| Income before tax | ¥61.3B | -¥47.5B | ¥137B | ¥119B | ¥26.4B | -¥107B | ¥151B | ¥28.2B | ¥134B | -¥52.5B | ¥163B | ¥156B | |
| Income tax | -¥44.5B | -¥44.5B | ¥41.3B | ¥27.3B | ¥2.57B | -¥4.2B | ¥26.4B | ¥39.9B | ¥30.1B | -¥28.2B | ¥49.5B | -¥36.5B | |
| Net income | ¥106B | -¥3.02B | ¥95.2B | ¥92B | ¥23.8B | -¥103B | ¥124B | -¥11.8B | ¥104B | -¥24.3B | ¥113B | ¥192B | |
| EPS (basic) | ¥67.38 | -¥1.92 | ¥60.71 | ¥58.14 | ¥15.03 | -¥65.25 | ¥79.40 | -¥7.48 | ¥65.61 | -¥15.56 | ¥71.65 | ¥123.15 | |
| EPS (diluted) | ¥66.70 | -¥1.92 | ¥59.94 | ¥57.17 | ¥14.58 | -¥65.25 | ¥78.23 | -¥7.48 | ¥64.68 | -¥15.56 | ¥70.54 | ¥123.15 | |
| Shares (basic, weighted) | 1.57B | 1.57B | 1.57B | 1.58B | 1.59B | 1.58B | 1.56B | 1.58B | 1.58B | 1.56B | 1.56B | 1.56B | |
| Shares (diluted, weighted) | 1.59B | 1.57B | 1.59B | 1.61B | 1.63B | 1.58B | 1.59B | 1.58B | 1.6B | 1.56B | 1.56B | 1.56B | |
| Depreciation & amortization | ¥187B | ¥187B | ¥192B | ¥192B | ¥187B | ¥190B | ¥182B | ¥185B | ¥191B | ¥164B | ¥163B | ¥108B | |
| EBITDA | ¥315B | ¥183B | ¥389B | ¥381B | ¥247B | ¥134B | ¥440B | ¥296B | ¥448B | ¥155B | ¥390B | ¥327B |
| Income statement | Trend | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | ¥1.73T | ¥1.77T | ¥2.1T | ¥3.29T | ¥3.2T | ¥3.57T | ¥4.03T | ¥4.26T | ¥4.58T | ¥4.51T | |
| Cost of revenue | ¥714B | ¥622B | ¥822B | ¥1.5T | ¥1.4T | ¥1.53T | ¥1.73T | ¥1.94T | ¥2.13T | ¥2.21T | |
| Gross profit | ¥1.02T | ¥1.15T | ¥1.28T | ¥1.79T | ¥1.8T | ¥2.04T | ¥2.3T | ¥2.32T | ¥2.46T | ¥2.3T | |
| Research & development | ¥312B | ¥325B | ¥368B | ¥492B | ¥456B | ¥526B | ¥633B | ¥729B | ¥730B | ¥676B | |
| Other operating expenses | ¥0 | ¥0 | -¥4.11B | ¥30.4B | ¥19.5B | ¥20.7B | ¥9.47B | ¥11.1B | -¥7.31B | ¥0 | |
| Operating expenses | ¥931B | ¥954B | ¥1.06T | ¥1.49T | ¥1.35T | ¥1.43T | ¥1.64T | ¥1.79T | ¥1.83T | ¥1.76T | |
| Operating income | ¥87B | ¥195B | ¥219B | ¥303B | ¥448B | ¥610B | ¥658B | ¥531B | ¥628B | ¥540B | |
| Interest income | ¥2.02B | ¥3.28B | ¥6.62B | ¥11.2B | ¥1.78B | ¥4.59B | ¥5.51B | ¥11.3B | ¥19.6B | ¥211B | |
| Interest expense | ¥10.5B | ¥12.7B | ¥68.2B | ¥159B | ¥148B | ¥142B | ¥136B | ¥154B | ¥187B | ¥358B | |
| Other non-operating income (gains on investments, FX ...) | -¥66.8B | -¥34.6B | ¥22.9B | ¥205B | -¥66.3B | ¥151B | ¥138B | ¥331B | ¥261B | -¥77.3B | |
| Total non-operating income | ¥56.4B | ¥21.9B | -¥91.1B | -¥363B | -¥81.4B | -¥308B | -¥283B | -¥479B | -¥452B | -¥280B | |
| Income before tax | ¥143B | ¥217B | ¥128B | -¥60.8B | ¥366B | ¥303B | ¥375B | ¥52.8B | ¥175B | ¥260B | |
| Income tax | ¥27.8B | ¥30.5B | -¥7.47B | -¥105B | -¥9.94B | ¥72.4B | ¥58.1B | -¥91.4B | ¥66.9B | ¥68.2B | |
| Net income | ¥115B | ¥187B | ¥135B | ¥44.2B | ¥376B | ¥230B | ¥317B | ¥144B | ¥108B | ¥192B | |
| EPS (basic) | ¥147.15 | ¥239.35 | ¥69.57 | ¥28.41 | ¥240.72 | ¥147.14 | ¥204.29 | ¥92.09 | ¥68.36 | ¥121.75 | |
| EPS (diluted) | ¥146.26 | ¥237.55 | ¥69.57 | ¥28.25 | ¥238.96 | ¥145.87 | ¥201.94 | ¥91.16 | ¥67.23 | ¥119.64 | |
| Shares (basic, weighted) | 781M | 781M | 961M | 1.56B | 1.56B | 1.56B | 1.55B | 1.56B | 1.58B | 1.58B | |
| Shares (diluted, weighted) | 786M | 787M | 967M | 1.57B | 1.57B | 1.58B | 1.57B | 1.58B | 1.61B | 1.6B | |
| Depreciation & amortization | ¥171B | ¥182B | ¥248B | ¥584B | ¥560B | ¥583B | ¥664B | ¥728B | ¥761B | ¥721B | |
| EBITDA | ¥325B | ¥412B | ¥443B | ¥681B | ¥1.07T | ¥1.04T | ¥1.18T | ¥928B | ¥1.13T | ¥1.34T |
Standardised by Financial Modeling Prep from the company's filings; outflows and costs keep the sign the provider reports. Hover a period for its end date. Amounts in JPY.
Revenue, operating income and growth
quarterlyMargins
quarterlyCosts as % of revenue
quarterlyThe other statements
Sources
Statements, segment revenue, metrics and estimates: Financial Modeling Prep.
Data as of 2026-11-01